Biochemical evaluation of safety and efficiency of VOSEVI drug as a treatment for HCV infected patients in Egypt

Hepatitis C disease is a disease caused by the action of the hepatitis C virus (HCV). Egypt has the highest percentage of HCV-4, which is accountable for nearly 90% of infections and is regarded as the major cause of chronic hepatitis. HCV-4 infected patients were poorly controlled with pegylated interferon-alpha (peg-IFN α) and ribavirin (RBV) therapy due to their side effects and low rate of response (60%). In this work we use VOSEVI combined therapy inhibitors of the HCV life cycle. VOSEVI consists of Sofosbuvir, an NS5B inhibitor of polymerase; Velpatasvir (an NS5A inhibitor); and Voxilaprivir, acts as an NS3/4A protease inhibitor. In this work we aimed to assess the safety and efficiency of using the (VOSEVI) drug among (HCV) infected patients from two large general hospitals in Fayoum, Egypt. 235 chronic HCV patients of both sexes (121 males and 114 females) were included. Our results show a reduction in serum ALT and AST, which was statistically significant (p < 0.001).There was also a statistically significant increase in serum creatinine and platelet count. There was a reduction in WBC count and haemoglobin, which was statistically significant (p < 0.001). There was a statistically significant improvement in FIB-4 scores following treatment. This means high improvement in liver fibrosis detected by FIB-4 and ABRI scores. Most of the patients have negative PCR results after 3 months of treatment (SVR at the end of therapy was 98.59%, and the SVR12 was 100%). Also, mild side effects were detected in only 12.3% while the rest showed no adverse effects. VOSEVI is an effective course of therapy with mild side effects for HCV patients.